FCGRT
ENSG00000104870
Target class
Unclassified protein
Chromosome
19
Approved drugs
2
Clinical candidates (approved and in development)
5
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- No
- Target name
- FCGRT
- Gene name
- Fc gamma receptor and transporter
- Gene symbol
- FCGRT
- Protein name
- IgG receptor FcRn large subunit p51 (FcRn) (IgG Fc fragment receptor transporter alpha chain) (Neonatal Fc receptor)
- FcgammaRn
- FcRn
- Gene biotype
- Protein coding
- Gene family
- C1-set domain containing
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 54
- Highest tissue expression
- 281.16
- Tissue specificity (Gini)
- 0.446
- Tissue specificity (tau)
- 0.682
- KEGG gene identifiers
- hsa:2217
- Protein interaction confidence
- 0.8635
- Protein interaction partners
- 10
- End position
- 49526917
- Start position
- 49506806
- Chromosome
- 19
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein . Endosome membrane .
Publication evidence
- PubMed 31104841
- Tissue specificity (tau)
- 0.681979
- Expression inequality (Gini)
- 0.446325
Expression in transcripts per million
- Spleen
- 281.16
- Cervix - Endocervix
- 260.83
- Cervix - Ectocervix
- 260.07
- Adipose - Subcutaneous
- 207.39
- Adipose - Visceral (Omentum)
- 206.86
Expression in transcripts per million
- Spleen281.16
- Cervix - Endocervix260.83
- Cervix - Ectocervix260.07
- Adipose - Subcutaneous207.39
- Adipose - Visceral (Omentum)206.86
- Ovary202.98
- Fallopian Tube192.1
- Lung184.96
- Nerve - Tibial180.25
- Breast - Mammary Tissue173.9
- Whole Blood171.56
- Small Intestine - Terminal Ileum169.47
- Uterus168.88
- Colon - Transverse142.5
- Artery - Coronary129.74
- Vagina124.38
- Thyroid121.48
- Liver111.59
- Bladder106.06
- Artery - Aorta105.36
- Prostate103.35
- Colon - Sigmoid100.46
- Esophagus - Gastroesophageal Junction95.59
- Skin - Sun Exposed (Lower leg)93.48
- Esophagus - Muscularis85.61
And 29 more, listed on the interactive page.
Cellular components
- GO:0010008
- GO:0005515
- GO:0019864
Related records
Trials (166)
- A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP
- A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
- A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
- A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults
- A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers
- A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
- A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
- A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
- A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
- A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)
- A Phase I Study Evaluating the Safety, Tolerability, PK and PD in Healthy Chinese Volunteers
- A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)
- A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis
- A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease
- A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome
- A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
- A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation
- A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
- A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack
- A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)
Drugs (6)
- Batoclimab IgG receptor FcRn large subunit p51 inhibitor
- Efgartigimod alfa IgG receptor FcRn large subunit p51 antagonist
- Nipocalimab IgG receptor FcRn large subunit p51 antagonist
- Orilanolimab IgG receptor FcRn large subunit p51 antagonist
- Rozanolixizumab IgG receptor FcRn large subunit p51 inhibitor
- Ziltivekimab